Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -38.75% is 26% below its 5-year average of -30.73%, around the middle of its 5-year range (-58.17%–-8.57%).
17.02% below its 12-month average of -33.11%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -11.88%.
RETURN ON ASSETS (ROA)
-38.75%
RETURN ON ASSETS (ROA) AVG TTM
-33.11%
RETURN ON ASSETS (ROA) AVG 3Y
-29.41%
RETURN ON ASSETS (ROA) AVG 5Y
-30.73%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-17.02%
CURRENT VS 3Y AVG
-31.78%
CURRENT VS 5Y AVG
-26.11%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-20.10%
vs the sector median at left
Tyra Biosciences, Inc.
Market Cap
$1.21B
Return on Assets (ROA)
-38.75%
TTM Avg
-33.11%
3Y Avg
-29.41%
5Y Avg
-30.73%
Market Cap
$1.21B
Return on Assets (ROA)
-49.10%
TTM Avg
-49.10%
3Y Avg
-49.10%
5Y Avg
-49.10%
Market Cap
$1.20B
Return on Assets (ROA)
-48.35%
TTM Avg
-102.84%
3Y Avg
-97.55%
5Y Avg
-75.48%
Market Cap
$1.22B
Return on Assets (ROA)
-0.46%
TTM Avg
-2.95%
3Y Avg
-4.25%
5Y Avg
-4.39%
Market Cap
$1.23B
Return on Assets (ROA)
5.91%
TTM Avg
1.36%
3Y Avg
-4.42%
5Y Avg
-8.30%
Market Cap
$1.18B
Return on Assets (ROA)
-5.96%
TTM Avg
3.87%
3Y Avg
-6.09%
5Y Avg
-17.05%
Market Cap
$1.23B
Return on Assets (ROA)
1.31%
TTM Avg
-17.71%
3Y Avg
-26.67%
5Y Avg
-26.67%
Market Cap
$1.24B
Return on Assets (ROA)
-34.68%
TTM Avg
-39.07%
3Y Avg
-38.32%
5Y Avg
-34.05%
Market Cap
$1.14B
Return on Assets (ROA)
-14.35%
TTM Avg
-48.83%
3Y Avg
-54.71%
5Y Avg
-49.10%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | $1.21B | -38.75% | -33.11% | -29.41% | -30.73% |
| Kardigan, Inc. (KARD)vs › | $1.21B | -49.10% | -49.10% | -49.10% | -49.10% |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.20B | -48.35% | -102.84% | -97.55% | -75.48% |
| Innovage Holding Corp. (INNV)vs › | $1.22B | -0.46% | -2.95% | -4.25% | -4.39% |
| Cronos Group Inc. (CRON)vs › | $1.23B | 5.91% | 1.36% | -4.42% | -8.30% |
| MannKind Corporation (MNKD)vs › | $1.18B | -5.96% | 3.87% | -6.09% | -17.05% |
| Omada Health (OMDA)vs › | $1.23B | 1.31% | -17.71% | -26.67% | -26.67% |
| ORIC Pharmaceuticals, Inc. (ORIC)vs › | $1.24B | -34.68% | -39.07% | -38.32% | -34.05% |
| Nektar Therapeutics (NKTR)vs › | $1.14B | -14.35% | -48.83% | -54.71% | -49.10% |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.14B | 4.50% | 8.06% | 9.38% | 7.83% |
ROA
-38.8%
ROE
-42.0%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -42.44% |
| 2024-12-31 | -23.79% |
| 2023-12-31 | -30.61% |
| 2022-12-31 | -20.78% |
| 2021-12-31 | -8.57% |
| 2020-12-31 | -58.17% |
| 2019-12-31 | -768.56% |
